175 related articles for article (PubMed ID: 34646963)
1. Stereotactic Ablative Radiation Therapy for Oligoprogressive Renal Cell Carcinoma.
Schoenhals JE; Mohamad O; Christie A; Zhang Y; Li D; Singla N; Bowman I; Arafat W; Hammers H; Courtney K; Cole S; Bagrodia A; Margulis V; Desai N; Garant A; Choy H; Timmerman R; Brugarolas J; Hannan R
Adv Radiat Oncol; 2021; 6(5):100692. PubMed ID: 34646963
[TBL] [Abstract][Full Text] [Related]
2. Phase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer.
Hannan R; Christensen M; Hammers H; Christie A; Paulman B; Lin D; Garant A; Arafat W; Courtney K; Bowman I; Cole S; Sher D; Ahn C; Choy H; Timmerman R; Brugarolas J
Eur Urol Oncol; 2022 Apr; 5(2):216-224. PubMed ID: 34986993
[TBL] [Abstract][Full Text] [Related]
3. The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review.
Le Guevelou J; Sargos P; Siva S; Ploussard G; Ost P; Gillessen S; Zilli T
Eur Urol Focus; 2023 Jan; 9(1):114-124. PubMed ID: 36151031
[TBL] [Abstract][Full Text] [Related]
4. Stereotactic Ablative Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer.
Hannan R; Christensen M; Christie A; Garant A; Pedrosa I; Robles L; Mannala S; Wang C; Hammers H; Arafat W; Courtney K; Bowman IA; Sher D; Ahn C; Cole S; Choy H; Timmerman R; Brugarolas J
Eur Urol Oncol; 2022 Dec; 5(6):695-703. PubMed ID: 35985982
[TBL] [Abstract][Full Text] [Related]
5. The impact of stereotactic ablative radiotherapy on oligoprogressive metastases from renal cell carcinoma.
Franzese C; Marini B; Baldaccini D; Badalamenti M; Navarria P; Bellu L; Franceschini D; Comito T; Clerici E; Teriaca MA; Massaro M; Di Cristina L; Lo Faro L; Tomatis S; Scorsetti M
J Cancer Res Clin Oncol; 2023 Jul; 149(8):4411-4417. PubMed ID: 36109401
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic Ablative Radiation Therapy for Large (≥5 cm) Non-small Cell Lung Carcinoma.
McDermott RL; Mihai A; Dunne M; Keys M; O'Sullivan S; Thirion P; ElBeltagi N; Armstrong JG
Clin Oncol (R Coll Radiol); 2021 May; 33(5):292-299. PubMed ID: 33309479
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of Stereotactic Ablative Radiotherapy for Systemic Therapy Respondents with Inoperable Pulmonary Oligometastases and Oligoprogression.
Ho CB; Tsai JT; Chen CY; Shiah HS; Chen HY; Ting LL; Kuo CC; Lai IC; Lai HY; Chung CL; Lee KL; Tzeng HE; Lee KH; Lee HL; Chen SW; Chiou JF
Diagnostics (Basel); 2023 Apr; 13(9):. PubMed ID: 37174988
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R
Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic Radiotherapy for Oligoprogression in Metastatic Renal Cell Cancer Patients Receiving Tyrosine Kinase Inhibitor Therapy: A Phase 2 Prospective Multicenter Study.
Cheung P; Patel S; North SA; Sahgal A; Chu W; Soliman H; Ahmad B; Winquist E; Niazi T; Patenaude F; Lim G; Heng DYC; Dubey A; Czaykowski P; Wong RKS; Swaminath A; Morgan SC; Mangat R; Keshavarzi S; Bjarnason GA
Eur Urol; 2021 Dec; 80(6):693-700. PubMed ID: 34399998
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer.
Zhang Y; Schoenhals J; Christie A; Mohamad O; Wang C; Bowman I; Singla N; Hammers H; Courtney K; Bagrodia A; Margulis V; Desai N; Garant A; Choy H; Timmerman R; Brugarolas J; Hannan R
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):367-375. PubMed ID: 31377159
[TBL] [Abstract][Full Text] [Related]
11. Definitive radiotherapy for extracranial oligoprogressive metastatic renal cell carcinoma as a strategy to defer systemic therapy escalation.
De B; Venkatesan AM; Msaouel P; Ghia AJ; Li J; Yeboa DN; Nguyen QN; Bishop AJ; Jonasch E; Shah AY; Campbell MT; Wang J; Zurita-Saavedra AJ; Karam JA; Wood CG; Matin SF; Tannir NM; Tang C
BJU Int; 2022 May; 129(5):610-620. PubMed ID: 34228889
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of High-Dose Stereotactic Ablative Radiotherapy to All/Multiple Sites for Oligometastatic Renal Cell Cancer Patients.
Ma MW; Li HZ; Gao XS; Liu MZ; Yin H; Yang KW; Chen JY; Ren XY; Wang D
Curr Oncol; 2022 Oct; 29(10):7832-7841. PubMed ID: 36290896
[TBL] [Abstract][Full Text] [Related]
13. Disease Control and Toxicity Outcomes after Stereotactic Ablative Radiation Therapy for Recurrent and/or Metastatic Cancers in Young-Adult and Pediatric Patients.
Upadhyay R; Klamer B; Matsui J; Chakravarthy VB; Scharschmidt T; Yeager N; Setty BA; Cripe TP; Roberts RD; Aldrink JH; Singh R; Raval RR; Palmer JD; Baliga S
Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893209
[TBL] [Abstract][Full Text] [Related]
14. Surgery for thoracic oligoprogression in metastatic renal cell cancer in the era of new systemic therapies.
Le UT; Passlick B; Schmid S
J Thorac Dis; 2023 Mar; 15(3):1133-1141. PubMed ID: 37065601
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic Radiation Therapy Combined With Immunotherapy Against Metastatic Melanoma: Long-Term Results of a Phase 1 Clinical Trial.
Ratnayake G; Reinwald S; Shackleton M; Moore M; Voskoboynik M; Ruben J; van Zelm MC; Yu D; Ward R; Smith R; Haydon A; Senthi S
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):150-156. PubMed ID: 32450331
[TBL] [Abstract][Full Text] [Related]
16. Five-year overall survival with ipilimumab and stereotactic ablative radiotherapy for metastatic disease.
He K; Hong DS; Tang C; Sezen D; Cox L; Maleki A; Bertolet G; Nguyen QN; Comeaux NI; Schuda L; Chen D; Welsh JW
Radiother Oncol; 2023 Jun; 183():109618. PubMed ID: 36921766
[TBL] [Abstract][Full Text] [Related]
17. Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
Blake-Cerda M; Lozano-Ruíz F; Maldonado-Magos F; de la Mata-Moya D; Díaz-García D; Lara-Mejía L; Zatarain-Barrón ZL; Cuevas-Góngora MF; Barron-Barron F; Corona-Cruz JF; Cabrera-Miranda L; Arroyo-Hernández M; Gerson R; Arrieta O
Lung Cancer; 2021 Feb; 152():119-126. PubMed ID: 33385737
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic ablative radiosurgery for locally advanced or recurrent skull base malignancies with prior external beam radiation therapy.
Xu KM; Quan K; Clump DA; Ferris RL; Heron DE
Front Oncol; 2015; 5():65. PubMed ID: 25853093
[TBL] [Abstract][Full Text] [Related]
19.
Bahig H; Tonneau M; Blais N; Wong P; Filion E; Campeau MP; Vu T; Al-Saleh A; Tehfé M; Florescu M; Roberge D; Masucci L; Richard C; Menard C; Routy B
Clin Transl Radiat Oncol; 2022 Mar; 33():115-119. PubMed ID: 35243022
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic Ablative Radiation (SAbR) for Oligometastatic RCC.
All S; Garant A; Hannan R
Semin Radiat Oncol; 2021 Jul; 31(3):227-234. PubMed ID: 34090649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
